VETORYL(R) (Trilostane) Receives FDA Approval

December 15, 2008

OVERLAND PARK, Kan., Dec. 15 /PRNewswire/ — Dechra Veterinary Products
LLC today announces that the company has received FDA approval to market
VETORYL(R) Capsules.

VETORYL Capsules contain the drug trilostane, which has been demonstrated
to be effective in the treatment of Cushing’s syndrome in dogs. VETORYL will
be indicated for use in pituitary-dependent hyperadrenocorticism, which
comprises the majority of cases of Cushing’s syndrome in dogs. Additionally,
VETORYL has received designation status as a Minor Use Drug for treatment of
hyperadrenocorticism caused by adrenal tumors — the first drug to receive an
approval for this indication and the first drug to receive a Minor Use
designation in dogs.

Mike Eldred, President of U.S. Operations, says, “We are very excited to
have approval to market this novel product in the U.S. Following its launch in
January, veterinarians will be able to source the product through our network
of distribution partners.”

Dechra Veterinary Products LLC, located in Overland Park, Kansas, is the
U.S. subsidiary of Dechra Pharmaceuticals PLC, a UK listed company focused on
international animal healthcare markets. Dechra currently markets a range of
specialized veterinary products in the U.S. For more information, please visit
http://www.dechra-us.com or call 866-933-2472.

SOURCE Dechra Veterinary Products LLC

Source: newswire

comments powered by Disqus